Back to results
US 12,653,874 B2Granted
Nant cancer vaccine
AssigneesImmunityBio, Inc., NantCell, Inc.
InventorsPatrick Soon-Shiong, Kayvan Niazi, Shahrooz Rabizadeh, Hans G. Klingemann, Laurent H. Boissel, Barry J. Simon
Life of this patent
Estimating the term…
Abstract
Cancer is treated using coordinated treatment regimens that uses various compounds and compositions that drive a tumor from the escape phase of cancer immunoediting to the elimination and equilibrium phase of cancer immunoediting.
Claims15
A method of treating cancer in a patient in need thereof, the method comprising:
- administering to the patient a sequence of therapeutics,
- wherein the sequence comprises Nab-paclitaxel, target activated natural killer (taNK) cells, wherein the taNK cells comprise a chimeric antigen receptor (CAR) comprising an extracellular domain having binding affinity for a tumor-specific antigen, and IL-15 or IL-15N72D;
- wherein the therapeutics are administered in cycles;
- and
- wherein within the cycle the Nab-paclitaxel and taNK cells are administered before the IL-15 or IL-15N72D.
2 more elements
Dependencies are inferred from the claim text.